Van koers
Haagse rechtspraak doet Amerikaanse koersen schommelen. Onder de titel ‘Angiotech clarifies Dutch court action’ bericht Businessweek dat een persbericht van Biosensors in combinatie met een research note van zakenbank Lehman Brothers over het Haagse vonnis in de zaak Angiotech-Occam/Biosensors eind vorige week een daling heeft veroorzaakt in de koers van het aandeel Angiotech. Een soort rectificatie van Lehman Brothers deed de koers weer stijgen.
“Biosensors said in a release that a Dutch judge had denied Angiotech's request for a preliminary injunction against sales of its Axxion drug-coated stent. However, the release went onto say the "judge ruled that Biosensors Axxion (drug-coated stent) does not infringe the European Patent" held by Angiotech.
Lehman issued a research note on Angiotech rival Conor Medsystems Inc., stating "the fact that Biosensors was able to prove non-infringement with a paclitaxel stent increases the likelihood of a positive outcome," for Conor. Conor and Angiotech are locked in legal battles in several countries over Angiotech's patents for using paclitaxel to coat stents.
Angiotech, in a statement, stressed that the Dutch court had denied the company's request for a "preliminary injunction" against Biosensors, but this did not mean its patent was invalid, adding the lawsuit had not even entered the full trial phase.”
As a result, Lehman issued a research note on Angiotech reading: "After clarifying the ruling, it appears to be much less of a positive for (Conor) and much less of a negative for (Angiotech) than we originally thought suggesting today's trading in both names may be overreactions."
Lees het bericht hier (Business Week, via de IPKat). Lees het vonnis hier ("`Het voorgaande voert tot de conclusie dat Occam naar voorlopig oordeel geen inbreuk maakt op conclusie 1. De overige conclusies zijn volgconclusies waarop dan evenmin inbreuk wordt gemaakt. 4.26. Het verweer van Occam dat EP 376 ongeldig is kan de voorzieningenrechter thans eveneens onbesproken laten.")
